Clinical trials: Autonomic Nervous System Disorders
Osteoarthritis, Rheumatoid Arthritis
Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-steroidal Anti-inflammatory Drug Treatment
The purpose of this study is to evaluate the safety of long-term treatment with HZT-501, a fixed-dose combination oral tablet of 800 mg ibuprofen and 26.6 mg famotidine for patients that require long-term NSAID treatment.
- Conditions
- Osteoarthritis, Rheumatoid Arthritis, Chronic Low Back Pain, Chronic Regional Pain Syndrome
- Trial name
- NCT00984815
- Testing
- HZT-501
- Where
- 4 sites in United States
- Volunteers
- 86 people
- Sponsor
- Amgen
Autoimmune Hemolytic Anemia
A Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia
The purpose of this study is to evaluate the safety and efficacy of parsaclisib administered orally to participants with autoimmune hemolytic anemia (AIHA) who have decreased hemoglobin and evidence of ongoing hemolysis that…
- Trial name
- NCT03538041
- Testing
- Parsaclisib
- Where
- 12 sites in United States, Austria and 2 more
- Volunteers
- 25 people
- Sponsor
- Incyte Corporation
Functional Gastrointestinal Disorders, Irritable Bowel Syndrome
Does Improving Vagal Tone Increase Mitochondrial Bioenergetics
This study evaluates the effect of auricular neurostimulation on mitochondrial bioenergetics and inflammation through vagal nerve modulation via non-invasive percutaneous electrical nerve field stimulator in children with…
- Conditions
- Functional Gastrointestinal Disorders, Irritable Bowel Syndrome, Dyspepsia, Functional Abdominal Pain Syndrome
- Trial name
- NCT03931330
- Testing
- Percutaneous neurostimulation
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Medical College of Wisconsin
Multiple System Atrophy
Progression Rate of MSA Under EGCG Supplementation as Anti-Aggregation-Approach
MSA is a rapidly progressive disorder with an average survival time of about 7 years after the first clinical manifestation. No potent symptomatic treatment is currently available.
- Trial name
- PROMESA (NCT02008721)
- Testing
- EGCG as putative neuroprotective agent
- Where
- 12 sites in Germany
- Volunteers
- 92 people
- Sponsor
- Dr. Johannes Levin
Dysautonomia, Familial, Baroreflex Failure Syndrome
Carbidopa for the Treatment of Excessive Blood Pressure Variability
The overall study objectives are to determine whether carbidopa (Lodosyn®) is safe and well tolerated and to assess whether it can inhibit catecholamine-induced paroxysmal hypertension and normalize or reduce the exaggerated…
- Trial name
- CarbiFD (NCT02553265)
- Testing
- Carbidopa Low-Dose, Carbidopa High-Dose
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- NYU Langone Health
Infant Apnea, Neonatal Abstinence Syndrome
Interventions to Help Infants Recover in the Hospital
This pilot project will evaluate independently two non-pharmacological interventions, 1) Neurosensory, Environmental Adaptive Technology (NEATCAP) and 2) Stochastic Vibrotactile Stimulation (SVS), as adjuvant non-pharmacological…
- Conditions
- Infant Apnea, Neonatal Abstinence Syndrome, Sleep
- Trial name
- NCT03881553
- Testing
- NEATCAP, SVS mattress
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Elisabeth Salisbury, PhD
Episodic Cluster Headache
A Study to Evaluate the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Episodic Cluster Headache (ECH)
This is a 13-week, multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group study to compare the efficacy and safety of 2 dose regimens of TEV-48125 (Fremanezumab) versus placebo in adult…
- Trial name
- NCT02945046
- Testing
- Fremanezumab
- Where
- 82 sites in United States, Australia and 10 more
- Volunteers
- 169 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Type 2 Diabetes, Inpatient
Effect of Glycemic Variability on Autonomic Tone in Hospitalized Patients With Type 2 Diabetes
Glycemic variability has been associated with mortality in hospitalized patients with hyperglycemia. However, it is unknown how modulation of glycemic variability would impact outcomes.
- Trial name
- NCT01409239
- Testing
- Intravenous insulin, Subcutaneous Insulin
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Kathleen Dungan
Autonomic Nervous System Imbalance, Blood Pressure
Short-term Cardiovascular Benefits of Wearing Particulate-filtering Respirators
An intervention study to assess the short-term cardiovascular effects of reducing personal air pollution exposure by wearing particulate filtering respirators.
- Conditions
- Autonomic Nervous System Imbalance, Blood Pressure, Inflammation, Vasoconstriction
- Trial name
- NCT02238028
- Testing
- Wear respirator
- Where
- China
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Fudan University
Diseases, Metabolic, Insulin Sensitivity
Comparing Soybean Oil-Based (Intralipid) With an Olive Oil-Based (ClinOleic) Lipid Emulsion on Healthy Volunteers
Many patients in the hospital who are malnourished or not eating received intravenous feeding or total parenteral nutrition (TPN). Despite improving nutrition, TPN may increase the risk of infections and hospital complications.
- Trial name
- TPN1 (NCT02185729)
- Testing
- Intralipid, ClinOleic, Dextrose
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Emory University
Small-cell Lung Cancer
Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250)
The main purpose of this study is to assess efficacy, safety, tolerability and pharmacokinetics (PK) of Berzosertib in combination with Topotecan in participants with relapsed, platinum-resistant small-cell lung cancer (SCLC).
- Trial name
- NCT04768296
- Testing
- Berzosertib, Topotecan
- Where
- 51 sites in United States, Belgium and 5 more
- Volunteers
- 76 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Diabetic Autonomic Neuropathy
Bromocriptine-QR Therapy on Sympathetic Tone and Vascular Biology in Type 2 Diabetes Subjects
The main objective is to demonstrate the effects of early dopaminergic activation on the autonomic nervous system in subjects with newly diagnosed vs. established type 2 diabetes.
- Trial name
- NCT02682901
- Testing
- Cycloset
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Eastern Virginia Medical School
Multiple System Atrophy
A Study of TAK-341 in Treatment of Multiple System Atrophy
The main aim is to see how TAK-341 works after 52 weeks in participants with multiple system atrophy as measured by the Unified Multiple System Atrophy Rating Scale Part I (UMSARS).
- Trial name
- NCT05526391
- Testing
- TAK-341
- Where
- 41 sites in United States, Austria and 8 more
- Volunteers
- 158 people
- Sponsor
- Takeda
Neurogenic Orthostatic Hypotension, Multiple System Atrophy (MSA) With Orthostatic Hypotension
TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)
This multiple-center, 3-part, single-blind dose escalation (Part A), randomized, double-blind (Part B), and open-label multiple dose extension (Part C) study will be conducted in male and female subjects with neurogenic…
- Conditions
- Neurogenic Orthostatic Hypotension, Multiple System Atrophy (MSA) With Orthostatic Hypotension, Pure Autonomic Failure, Parkinson Disease
- Trial name
- NCT02705755
- Testing
- TD-9855
- Where
- 6 sites in United States
- Volunteers
- 34 people
- Sponsor
- Theravance Biopharma
Multiple System Atrophy
Safinamide for Multiple System Atrophy (MSA)
The study is a placebo controlled study, with two parallel arms, in which participants will be randomly assigned in a 2:1 ratio to receive either active (200 mg safinamide) or placebo in a double blind manner.
- Trial name
- NCT03753763
- Testing
- Safinamide Methanesulfonate
- Where
- 19 sites in Italy, Spain
- Volunteers
- 49 people
- Sponsor
- Zambon SpA
Breast Cancer
Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments
This was a Phase II, multicenter, open-label, three-cohort, non-comparative study of alpelisib plus endocrine therapy (either fulvestrant or letrozole) in subjects (pre- and post-menopausal women and men) with HR-positive…
- Trial name
- BYLieve (NCT03056755)
- Testing
- Alpelisib, Fulvestrant, Letrozole
- Where
- 94 sites in United States, Argentina and 17 more
- Volunteers
- 383 people
- Sponsor
- Novartis Pharmaceuticals
Orthostatic Hypotension
An Open Label Trial to Decrease Signs and Symptoms of Orthostatic Hypotension Using Midodrine or Intravenous Fluid Bolus in Patients Following Total Hip Arthroplasty
Orthostatic hypotension following total hip arthroplasty is known to limit the ability of patients to perform physical therapy (PT) and increase the length of hospital stay and costs.
- Trial name
- NCT02154243
- Testing
- Midodrine, Intravenous fluid bolus
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Hospital for Special Surgery, New York
Complex Regional Pain Syndrome (CRPS)
Mechanism and Treatment of Sympathetically Maintained Pain
40 CRPS patients will be recruited over a three-year period (target of 160 patients at all sites). Assessment of exclusion criteria will be undertaken during initial recruitment.
- Trial name
- NCT01813149
- Testing
- phenylephrine and clonidine, punch biopsy
- Where
- United States
- Volunteers
- 128 people
- Sponsor
- The Cleveland Clinic
Muscle Weakness
Controlled Trial of 3,4-Diaminopyridine (3-4DAP) in Lambert-Eaton Myasthenic Syndrome (LEMS)
The main purpose for this study is to provide access to 3,4 DAP, a drug which has demonstrated to be effective in treating weakness associated with Lambert-Eaton Myasthenic Syndrome.
- Trial name
- 3-4DAP (NCT02090725)
- Testing
- 3-4 Diaminopyridine
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Jeffrey A. Cohen, MD
Pulmonary Disease, Chronic Obstructive
Effects of Salmeterol on Autonomic Nervous System
This is a 4-week non-randomized, partially blinded, single-arm monocentre study in subjects with Chronic Obstructive Pulmonary Disease (COPD) Global Initiative for Chronic Obstructive Lung Disease (GOLD) class II or III with the…
- Trial name
- ESAN (NCT01536587)
- Testing
- Salmeterol
- Where
- Germany
- Volunteers
- 32 people
- Sponsor
- GlaxoSmithKline